

# BioWin Day 2021

Wallonia, the beating heart of European health innovation



#15ybiowin

**BIOWIN**  
THE HEALTH CLUSTER OF WALLONIA

**9 December 2021 - 10:00 – 17:00 CET ● 150 minutes of virtual plenary session ● 5 digital roundtables animated by our sponsors GSK, Pharmalex, PWC, Ayming, Belfius and Janssen Belgium in the afternoon ● 15 days of online matchmaking ● Virtual exhibition**

[REGISTER NOW](#)

---

[DISCOVER THE PROGRAM](#)

---

[MORNING PLENARY SESSIONS](#)

**10.00 – 10.05: Welcome & introduction**



**Sylvie Ponchaut**, Managing Director at BioWin - Belgium

## 10.05 – 10.15: 15 years of innovation in review



**Philippe Denoël**, PhD, Head of External R&D at GSK & Chairman of the Board of BioWin - Belgium

## Overview of four specific challenges for the next decade

### 10.15 – 10.40: Challenge 1:

#### Cell & gene therapies: opportunities & challenges in Belgium and Europe

Cell and gene therapies are at the forefront of innovation and transforming how we treat and potentially cure certain diseases.

But what will the next decade hold for these life-changing therapies?

The two speakers will discuss the main challenges for this promising sector and also the opportunities to be seized.



**Lieven Comeyne**, Partner | Supply Chain & Operations at Deloitte Belgium - Belgium



**Ingrid Marchal-Gérez**, EMEA Cell & Customer Journey Manager (CAR-T) at Janssen Pharmaceutica – France

### 10.40 – 11.05: Challenge 2:

#### Rethinking innovation in biomanufacturing: challenges & opportunities

For several years, biotherapeutic approaches have been making impressive progress in the pharmaceutical sector. The biomanufacturing value chain in Wallonia has a strong potential but needs to consolidate its position on this highly competitive international market. What are the innovative approaches and how are they integrated in the processes? How to achieve the ambition to position Wallonia among the European leaders in this field? Univercells will present its vision of this global evolution, as well as its strategy to actively participate in this challenge.



**Jose Castillo**, Co-founder & CTO at Univercells – Belgium

### 11.05 – 11.30: Challenge 3: Smart use of patient data for R&I: are we ready?

The smart use of patient data has the potential to open new fields in research and innovation, healthcare practices and precision medicine.

But are we ready for this challenge which is in the priority in the European agenda?

During this session, three speakers will share their ongoing initiatives and express their view on the challenges and perspectives.



**Ingrid Maes**, Manager at Inovigate



**Benoit Debande**, CEO at Groupe Hospitalier CHIREC



**Prof. Dr. Philippe Lambin**, MD, PhD, Maastricht University, Cofounder of Radiomics, Comunicare, Convert Pharma & Livingmed Biotech

### 11.30 – 11.55: Challenge 4: Overcoming biotech talent scarcity: 3 European initiatives

Many bioregions around the world are currently facing an unprecedented talent shortage. How to train faster and better anchor knowledge, how to support reconversions between fields? The 3 speakers will talk about 3 different and complementary initiatives: The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland, the Campus Biotech Digital in France and finally the European Biotech Campus, an initiative developed within the framework of the Recovery Plan.



**Karim Vissandjee**, General Manager at Campus Biotech Digital - France



**Killian O'Driscoll**, Director of projects at NIBRT - Ireland



**Didier Malherbe**, Managing Director at EU Biotech Campus – Belgium

### 11.55 – 12.10: Belgian innovation in the heart of Europe

The ecosystem of Biotech and life sciences companies in Belgium has been accelerating fast over recent years. Not only have some of the most visible companies such as Argen-X and Iteos made big headlines on the global stage, the next generation of companies such as Confo-therapeutics, Orionis Biosciences and Biotalys are lining up to enter the next leg of their global journey. Finally, the start-up scene has been extremely active over the most recent years and some of these are going through a spectacular growth, with examples as Muna Therapeutics, Exevir and Flamingo Therapeutics.

The current success of the Belgian ecosystem can be reduced to an intricate interplay of many aspects: world-class biomedical and agro-biotechnological research, entrepreneurial tech transfer practices, growing pools of companies and talented entrepreneurs and not in the least the long-term support of the supportive governments. The sector is high tech, but an important driver for the future position of Belgium as a global driver. VIB has been a central driver behind this expanding ecosystem in Flanders and the speaker will elaborate on how this was achieved.



**Jérôme Van Biervliet**, General Manager at VIB – Belgium

### 12.10 – 12.30: How to consolidate the Belgian health & biotech valley? Strategy and ambition for the next decade.



**Thomas Dermine**, State Secretary for Economic Recovery and Strategic Investments, in charge of Science Policy, added to the Minister of the Economy and Employment – Belgium